Showing results (1-10 of 36) with videos related to
Sort By:
Pageof 4
Metabolism: Clinical and Experimental|January 24, 1998
The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitroR C O'Brien, M LuoAtherosclerosis|March 8, 2000
Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practiceP J Barter, R C O'BrienDiabetic Medicine : a Journal of the British Diabetic Association|June 10, 2014
A justification for less restrictive guidelines on the use of metformin in stable chronic renal failureW R Adam, R C O'BrienGeneral Pharmacology|January 1, 1988
A pharmacological study of hibernation in rodentsC P Lyman, R C O'BrienJournal of Diabetes and Its Complications|September 27, 2000
In vitro and in vivo antioxidant properties of gliclazideR C O'Brien, M Luo, N Balazs, et al.Journal of Toxicology and Environmental Health|January 1, 1976
Quantitative relationship of fecal asbestos to asbestos exposureH M Cunningham, R D Pontefract, R C O'BrienClinical Science (London, England : 1979)|October 29, 2000
Vasodilator prostanoids, but not nitric oxide, may account for skeletal muscle hyperaemia in Type I diabetes mellitusR A Skyrme-Jones, R C O'Brien, I T MeredithDiabetes|April 1, 1993
The effects of perindopril and triple therapy in a normotensive model of diabetic nephropathyR C O'Brien, M E Cooper, G Jerums, et al.Clinical and Experimental Pharmacology & Physiology|August 1, 1989
Ramipril reduces albuminuria in diabetic rats fed a high protein dietR C O'Brien, M E Cooper, T J Allen, et al.Journal of the American Geriatrics Society|January 1, 1990
The use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosisL A Bach, M E Cooper, R C O'Brien, et al.Pageof 4